Compare · COO vs STAA
COO vs STAA
Side-by-side comparison of The Cooper Companies Inc. (COO) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COO and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 16.4x STAA ($1.16B).
- STAA has hit the wire 11 times in the past 4 weeks while COO has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- The Cooper Companies Inc.
- STAAR Surgical Company
- Price
- -
- -
- Market cap
- $19.03B
- $1.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 25
- 25
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest COO
- CooperCompanies Announces Release Date for Third Quarter 2026
- UBS initiated coverage on Cooper with a new price target
- SEC Form 4 filed by Director Keel Paul A
- SEC Form 3 filed by new insider Keel Paul A
- CooperSurgical Supports Saving Mothers to Help Advance Global Women’s Health and Raise Awareness
- CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure
- SEC Form 10-Q filed by The Cooper Companies Inc.
- Needham reiterated coverage on Cooper with a new price target
- SEC Form 8-K filed by The Cooper Companies Inc.
- CooperCompanies Announces Second Quarter 2026 Results
Latest STAA
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports Second Quarter 2026 Results
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- President and CEO Foust Warren converted options into 20,787 shares and covered exercise/tax liability with 10,576 shares, increasing direct ownership by 13% to 86,556 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 34,742 shares and covered exercise/tax liability with 17,056 shares, increasing direct ownership by 95% to 36,339 units (SEC Form 4)
- STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer